Add like
Add dislike
Add to saved papers

Preparation of an epitope-based recombinant diagnostic antigen specific to anti-phospholipase A 2 receptor 1 antibodies.

BMC Biotechnology 2018 May 30
BACKGROUND: According to recent studies, the phospholipase A2 receptor 1 (PLA2 R1) may be used as a biomarker to diagnose idiopathic membranous nephropathy (iMN). Moreover, the immune-dominant regions of PLA2 R1 have been identified. The aim of the present study was to construct a diagnostic antigen based on the immune-dominant region of PLA2 R1 and develop a specific serological detection method for PLA2 R1 antibodies.

RESULTS: The tandem multi-epitope diagnostic antigen (designated 'R101'), which includes aa 39-130 (CysR), aa 238-356 (CTLD1), and aa 1136-1234 (CTLD7) of PLA2 R1; thioredoxin at the N-terminus; and a His tag at the C-terminus, was prepared at a concentration of 2.36 mg/mL and purity of 97.32% using Escherichia coli expression and affinity and anion exchange chromatography purification. The integrity and antigenicity of the R101 protein was demonstrated by western blot analysis using anti-Trx, anti-His, and anti-PLA2 R1 monoclonal antibodies as the primary antibodies. By analysing 120 positive serum samples identified by biopsy-proven iMN (gold standard) and 240 negative samples identified by an established ELISA based on R101 protein, we concluded that the cut-off value, kappa value, sensitivity, specificity, and agreement rate were 0.305, 0.881, 91.67, 96.25, and 94.72% respectively. The receiver operating characteristic (ROC) curve illustrated that the diagnostic accuracy and practicability of the ELISA was excellent. The area under the curve was 0.986.

CONCLUSIONS: Using prokaryotic expression and chromatography purification, immune-dominant regions of PLA2 R1 with excellent antigenicity can be prepared and applied to serological detection of PLA2 R1 antibodies.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app